Emerging options in growth hormone therapy: an update

Stephen F Kemp
J Paul Frindik
University of Arkansas for Medical Sciences, Arkansas Children’s Hospital, Little Rock, AR, USA

Abstract: Growth hormone (GH) was first used to treat a patient in 1958. For the next 25 years it was available only from cadaver sources, which was of concern because of safety considerations and short supply. In 1985, GH produced by recombinant DNA techniques became available, expanding its possible uses. Since that time there have been three indications approved by the US Food and Drug Administration (FDA) for GH-deficiency states and nine indications approved for non-GH-deficiency states. In 2003 the FDA approved GH for use in idiopathic short stature (ISS), which may indirectly cover other diagnoses that have short stature as a feature. However, coverage for GH therapy is usually more reliably obtainable for a specific indication, rather than the ISS indication. Possible future uses for GH therapy could include the treatment of syndromes such as Russell–Silver syndrome or chondrodystrophy. Other non-short-stature indications could include wound healing and burns. Other uses that have been poorly studied include aging and physical performance, in spite of the interest already shown by elite athletes in using GH. The safety profile of GH developed over the past 25 years has shown it to be a very safe hormone with few adverse events associated with it. The challenge for the future is to follow these patients into adulthood to determine whether GH therapy poses any long-term risks.

Keywords: growth hormone, somatotropin, anabolic, short stature

Background

The first report of the use of growth hormone (GH) therapy for GH deficiency (GHD) was in 1958. Early GH preparations used therapeutically were derived from human cadaver pituitaries. In the USA, human-derived GH was produced and distributed by the National Institute of Health’s (NIH) National Pituitary Agency. The preparation was in short supply, resulting in lower than ideal dosing and frequent drug holidays. Potential recipients were required to participate in a research protocol and, to ration the cadaveric GH, the diagnosis of GHD required that the patient have a peak GH level in response to provocative stimuli below a certain level. This requirement gradually increased in response to a better supply of cadaveric GH, starting at 5 ng/mL, then 7 ng/mL, and finally 10 ng/mL in the early 1980s. In 1985 this preparation was linked to a risk for Creuzfeldt–Jacob disease, and its use was discontinued. In 1979 GH was produced in large quantities by expressing the human GH gene in *Escherichia coli*. In 1985, Genentech Inc (San Francisco, CA) was approved by the US Food and Drug Administration (FDA) to market recombinant human GH (rhGH), a product identical to human GH with the addition of a methionine, which was necessary as a start signal for the bacteria to initiate protein synthesis. Use of methionyl GH did result in antibody production, but this was rarely associated with growth attenuation. Present-day
commercial preparations all have the identical 191 amino acid sequence of native human pituitary hormone.\(^7\)

Initially GH was injected intramuscularly, but in the mid-1980s (about the time rhGH was introduced), it was shown to be as effective if given as a subcutaneous injection,\(^8\) which remains the practice today. Early in its use, GH was given twice weekly but this was was increased to three to five times weekly when the higher frequency was shown to result in an increased growth response.\(^9\) At about the time of the transition from cadaveric GH to rhGH, it was demonstrated that daily doses (six or seven injections per week) yielded an even better growth response than the three times per week schedule,\(^10\)–\(^13\) and daily administration is commonly used today. It is now clear from data from large databases\(^14\)–\(^16\) that GH-deficient children treated with GH are frequently achieving adult heights in the normal adult range, probably as a result of more aggressive dosing, dividing the dose into daily injections, and, perhaps, earlier initiation of treatment.

Since 1985 there have been eight indications for GH therapy in children approved by the FDA, and an additional indication for increasing the dose during puberty (see Table 1). There have also been three indications for GH use in adults. The basis for these indications has recently been reviewed.\(^17\)

Fifteen years ago, Hintz\(^18\) reviewed current and potential uses of GH. At that time, GH was already FDA approved in childhood GHD and chronic renal insufficiency, and adult GHD, Turner syndrome, and acquired immune deficiency syndrome (AIDS) wasting were on the brink of FDA approval.

Hintz predicted that other indications that might eventually have FDA approval for treatment of short stature included what he referred to as “non-growth hormone deficient short stature,” which we now call “idiopathic short stature” (ISS), skeletal dysplasia, spina bifida, rickets, Prader–Willi syndrome, and Down syndrome. Of these indications, Prader–Willi syndrome was FDA approved in 2000 and ISS was approved in 2003. The ISS indication has also been approved in Canada and parts of Latin America, although there has not yet been approval in Europe. FDA approval of the USA is limited to non-GHD patients whose height is >2.25 standard deviations (SDs) below the mean, who have predicted adult heights that are >2 SDs below the mean, who have open epiphyses, and who have no other condition that would better be treated by other means or by observation. There has also been interest in the use of GH as an anabolic agent in situations in which stature is not of paramount importance. Certainly, the anabolic effects of GH are of primary importance in the treatment of adults with GHD, where it has been shown to reduce accumulation of intra-abdominal fat, reverse high levels of low-density lipoprotein cholesterol, increase bone mineral density, and reverse some of the symptoms of fatigue. In the treatment of Prader–Willi syndrome, one of the benefits is increase in muscle mass at the expense of fat mass, which serves to improve overall body composition along with improvement in hypotonia, which is a major feature of the syndrome. However, it should be pointed out that FDA approval of treatment of Prader–Willi syndrome was limited to being for the short stature that is a part of the syndrome.

Other possible uses for GH that Hintz\(^18\) mentions include non-islet cell tumor hypoglycemia, fertility, aging, wound healing, cancer cachexia, and amyotrophic lateral sclerosis.

### Table 1: Approved indications for GH use in the USA and Europe

<table>
<thead>
<tr>
<th>Indication</th>
<th>Year of FDA approval</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GH-deficiency states</strong></td>
<td></td>
</tr>
<tr>
<td>Childhood growth-hormone deficiency</td>
<td>1985 (E)</td>
</tr>
<tr>
<td>Adult growth-hormone deficiency</td>
<td>1996 (E)</td>
</tr>
<tr>
<td>Pubertal dosing</td>
<td>2000</td>
</tr>
<tr>
<td><strong>Non-GH-deficiency states</strong></td>
<td></td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>1993 (E)</td>
</tr>
<tr>
<td>Turner syndrome</td>
<td>1996 (E)</td>
</tr>
<tr>
<td>AIDS wasting</td>
<td>1996</td>
</tr>
<tr>
<td>Prader–Willi syndrome</td>
<td>2000 (E)</td>
</tr>
<tr>
<td>Small for gestational age</td>
<td>2001 (E)</td>
</tr>
<tr>
<td>Idiopathic short stature</td>
<td>2003</td>
</tr>
<tr>
<td>Small bowel syndrome</td>
<td>2004</td>
</tr>
<tr>
<td>SHOX deletion</td>
<td>2006 (E)</td>
</tr>
<tr>
<td>Noonan syndrome</td>
<td>2007</td>
</tr>
</tbody>
</table>

Abbreviations: E, Europe; FDA, US Food and Drug Administration; GH, growth hormone.

### Potential indications for increased height

FDA approval of the ISS indication in 2003 has allowed GH to be used for a number of diagnoses that are not GHD. However, it has been difficult to get payers to cover the cost of treating ISS with GH. It is recognized that ISS represents a heterogeneous group of patients who are experiencing growth failure for a variety of reasons, and as more is understood about the etiology of growth failure, many of these patients will have more specific diagnoses. Screening of ISS patients for abnormalities in the SHOX gene has been a logical step. Out of 91 patients with ISS screened, Rao et al reported one patient with a functionally significantly mutation in the \textit{SHOX} gene.\(^19\) Ogata expanded the screen to include 400 patients with ISS, and found the aforementioned patient, along with
three others had SHOX gene mutations. In an analysis of 68 patients with ISS, one female patient was identified who had a normal karyotype but a deletion of one SHOX allele.

Other genes that have recently been discovered to result in growth failure include defects in the GH receptor's intracellular signaling, in particular STAT5b, and a defect in the acid-labile subunit (ALS) of the circulating insulin-like growth factor 1 (IGF-1) complex. STAT5b deficiency results in a phenotype of GH insensitivity and immunodeficiency, while ALS-deficient patients have rather subtle growth failure with height tracking at about or just below the third percentile. Neither of these defects has been identified in patients diagnosed as having ISS, perhaps in part because they represent very rare disorders. Also, it has been pointed out that the phenotype of STAT5b deficiency is that of severe GH resistance, and it is not likely to be mistaken for ISS. Perhaps ALS deficiency has not been identified in a population of ISS patients because the growth failure associated with it is too subtle for the affected child to be labeled as having ISS.

It appears that mutations in the GH receptor and the SHOX gene account for 1%–5% of the cases of growth failure that are designated ISS. As we recognize various causes for ISS, the pool of children with this designation should continue to decrease.

An analysis of patients in a large database showed that, between 1985 (when rhGH was first used) and 2003, over 8000 patients had been treated for ISS at a time when the database included data from 47,226 total patients. When subgroups of these patients were evaluated for their growth patterns, it was clear that they started GH therapy with very low height (−3.2 to −2.8 SD). Except for those who had been in puberty at the start of therapy, patients were followed for 7 years, at which time mean heights were −1 to −1.2 SD.

What have been the repercussions relating to the FDA approval of ISS as an indication for GH treatment? A comparison was made of data in the National Cooperative Growth Study from children who were treated for ISS before 2003 and those treated from 2003 to 2006 (ie, after FDA approval). Although no major changes were seen, there was a very small decrease in the severity of the growth retardation at entry and a slight increase in the treatment doses. Mean height velocities during treatment were the same before and after FDA approval.

An evaluation of ISS patients
Since FDA approval of GH treatment for ISS in 2003, there have been several new indications that are for conditions or syndromes in which short stature is part of the condition. To date, these have included the SHOX deletion (including Léri–Weill syndrome) and Noonan syndrome. Another possible situation in which GH might be used would be for children with skeletal dysplasias. However, a recent study suggests that children with skeletal dysplasias respond poorly to GH therapy. A previous study evaluated 5 years of GH therapy in 35 children with achondroplasia. Patients were randomized to one of two dosing arms: 0.1 IU/kg or 0.2 IU/kg. The group receiving the higher dose increased their average height by 0.8 SD during the study; the group receiving the lower dose increased their average height by 0.6 SD. They saw no change in body proportions or arm span.

There has also been some interest in treating children with Russell–Silver syndrome with GH. A recent study treated 26 patients with Russell–Silver syndrome to adult height (median treatment time: 9.8 years). Over this time, the mean height SD of the patients increased from −2.7 to −1.3. It was also noted that those patients with the shortest height SD at the beginning of GH therapy were the ones that gained the most height with treatment.

Hypophosphatemic rickets
Hypophosphatemic rickets also includes, autosomal dominant hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, tumor-induced osteomalacia, and fibrous dysplasia. All of these disorders are characterized by low levels of serum phosphate, which does not allow good function of mature osteoblasts, leading to poor linear growth. X-linked hypophosphatemic rickets (XLHR) is the most common form of hypophosphatemic rickets. Conventional therapy has included supplementation with oral phosphate and vitamin D. Growth response to conventional therapy is disappointing, in part because oral phosphate is unpalatable and there is often noncompliance. Since the advent of recombinant GH, there has been interest in investigating whether GH would increase the growth response (and ultimately adult height) in patients with this disorder. Due to the rare nature of the disorder, such studies have been limited because of the small numbers of subjects studied. Saggese et al studied twelve subjects, of whom six received conventional therapy plus GH and six received only conventional therapy. They concluded that those receiving GH showed an increase in height Z-score, growth velocity Z-score, and predicted adult height, along with increases in serum phosphate, bone markers, bone alkaline phosphatase, parathyroid hormone, 1,25-hydroxy vitamin D, and bone mineral density. Reusz et al similarly treated
six children with XLHR with GH, and showed an increase in height Z-score and a slight increase in serum phosphate.\textsuperscript{35} However, there was no control group in this study. Wilson reviewed seven clinical trials and concluded that GH appeared to increase growth velocity, although there were no adult height data.\textsuperscript{36} He did note that GH therapy appeared to be safe. A subsequent study did report adult height data in a study of treating twelve patients with XLHR (six treated with conventional therapy plus GH, and six treated only with conventional therapy).\textsuperscript{37} These results showed that GH treatment for as long as 10 years was associated with an increase in height SD score of 1 SD at the time adult height was achieved. Another analysis of published data by Huiming and Chaomin found that, of the five published trials they found, only one met their inclusion criteria.\textsuperscript{38} This trial included only five participants, but it did show an increase in height SD score with GH. However, their conclusion was that there was no conclusive evidence that GH therapy in XLHR increased linear growth, changed mineral metabolism, renal function, bone mineral density, or body proportions. However, GH therapy did appear to be safe.

It seems clear, therefore, that treatment with GH is safe for hypophosphatemic rickets, but it is not yet possible to say whether GH treatment is truly effective, or, if there is a growth response, how large an increase in adult height there would be. More investigation with appropriate controls and greater numbers of subjects is necessary before it can be conclusively determined that GH is of benefit in this condition.

Psychological aspects of treating short stature with GH

It is assumed that short stature is associated with disadvantages and problems of psychological adjustment. Anecdotal reports include teasing, treating children in relation to their height rather than their age (juvenilization), and academic underachievement.\textsuperscript{39} Some studies seem to confirm these notions,\textsuperscript{40–43} while others have failed to demonstrate any disadvantage to short stature, including any problem with psychological adjustment.\textsuperscript{44–47} In fact, Kranzler et al\textsuperscript{48} evaluated 90 children who were sent to a stature clinic and determined that, in fact, they had normal psychological function without externalizing behavior problems, attention problems, or poor social skills, as had been previous reported.\textsuperscript{42,49,50} Sandberg et al reported that juvenilization does occur, but short stature is not associated with any social disadvantage.\textsuperscript{51} Balen et al have suggested that patients referred for ISS seem to be more at risk for psychological problems than those who are not referred.\textsuperscript{52} Further, they indicate that in addition to stature there are other risk factors for psychological difficulty, including: being juvenilized, being male, having low intelligence, having a younger but taller sibling, and being part of a family with low socioeconomic status. In light of this controversy, it is not surprising that it has been difficult to demonstrate that treatment of short stature improves the quality of life of the individual. Many physicians who treat children with ISS believe that by increasing adult height they are improving quality of life;\textsuperscript{53} however, there are few objective data to support this notion.\textsuperscript{54} In fact, the idea that short stature is a problem that can be addressed by GH treatment has been recently challenged in the popular press.\textsuperscript{55} Recent reviews of available instruments for evaluating quality of life in children with GHD or ISS suggest that it should be possible to do studies that could help answer whether treatment with GH has a positive or negative effect on quality of life.\textsuperscript{56,57} Chaplin et al have recently published a study on the effect of GH therapy on behavior and psychosocial characteristics in 99 short children treated with GH (32 with GHD and 67 with ISS).\textsuperscript{58} They demonstrated that at baseline these children showed higher levels of internalizing behavior and self-esteem compared with reference values. With GH treatment, behavior measures and depression became closer to the population mean at 3 months. Further, this change was maintained for as long as 24 months. We should expect further studies along this line to know whether GH therapy for short stature is effective beyond merely making children taller. This question is particularly relevant because of the expense of GH therapy – which costs perhaps as much as US$52,634/inch.\textsuperscript{59} Savage has suggested that for non-GHD short stature, (1) if GH therapy is restricted to a height threshold of \(-2.5\) or \(-3.0\) SD and, (2) if treatment is limited to those children with slow height velocity, there might be fewer children who would experience a benefit in terms of taller stature that could have been attained without treatment.\textsuperscript{60}

As previously discussed,\textsuperscript{61} there are a number of reasons to treat children with ISS, the most important of which is that it does not seem appropriate to withhold treatment from them just because the etiology for their extreme short stature has not yet been discovered. With time there will likely be a larger group of patients in which the etiology of their short stature is elucidated. Other approaches to treating ISS include treating
with IGF-I (alone or in combination with GH), which has the added risk of adverse events, or delaying puberty, either with LHRH agonists or with an aromatase inhibitor. Both of these approaches are still in experimental stages.

Potential indications, both height-related and anabolic

Cystic fibrosis

Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutation of the CF transmembrane regulator protein, which regulates sodium and chloride transport across epithelial membranes. CF is characterized by viscous secretions of exocrine glands, endocrine pancreas insufficiency, as well as growth failure and malnutrition. Since the advent of recombinant GH there has been interest in using GH to treat the growth issues, as well as to help address some of the nutritional problems relating to their increased energy expenditure. Several studies have suggested that GH therapy in CF increases growth velocity as well as weight. A recent study evaluated ten controlled clinical trials and eight observational studies. In the controlled trials, markers of pulmonary function, anthropometrics, and bone mineralization all appeared to be increased compared with controls. The single-case studies tended to support these findings. With regard to long-term health issues, such as pulmonary exacerbations, hospitalizations, or mortality, the only significant finding was that GH therapy seemed to reduce the rate of hospitalizations. Therefore, data for treatment of CF appear promising but more studies are necessary to determine whether there are long-term benefits of this treatment.

Potential nonheight-related indications

Critically ill patients

In the 1990s, there was interest in treating catabolic patients with GH. Two large placebo-controlled studies were undertaken in intensive care patients who had heart or abdominal surgery, trauma, or acute respiratory failure. Both studies were concluded early when an interim evaluation of the data demonstrated that the mortality rate in both studies was significantly higher in those patients receiving GH (41.9% versus 19.3%). It is now recommended not to treat critically ill patients with GH, especially patients with an active infection or sepsis.

Burns

GH was used soon after recombinant GH was available to increase donor site healing in patients with severe burns. Lal et al demonstrated that patients receiving large doses of GH (0.2 mg/kg/day) had an approximately 14-day decrease in length of stay. Because of concern about increased mortality seen in critically ill adults, they compared mortality rates between these patients and a control group. Mortality rates for those receiving GH were not different from controls.

Aging

It has been noted that there is a decline of about 14% per decade of age in the levels of both GH and IGF-I. Because some of the signs of human aging, such as decreased muscle and bone mass, dyslipidemia, and psychological symptoms, are similar to what has been seen with adult GHD, it has been suggested that these signs of aging may be due, at least in part, to the low levels of GH and IGF-I, and has even been given the description “somatopause.” Unfortunately, studies using GH replacement in subjects with somatopause have been somewhat disappointing.

Physical performance

The problem of the use of GH as a performance enhancer has been well recognized in the world of sports. It is used for its anabolic and lipolytic properties in an attempt to improve performance and shorten recovery times after injury. In studies with healthy untrained men, addition of GH to resistance training for 12 weeks failed to increase muscle strength beyond what was gained by training alone. Further, Yarasheski et al have demonstrated that GH administration does not increase muscle protein synthesis in experienced weight lifters. However, Birzniece et al have suggested that GH could affect utilization of metabolic fuels during exercise, leading to enhancement of exercise capacity. Although GH does increase lean body mass, Birzniece et al suggest that it is likely due to fluid retention, rather than increased muscle mass. These authors acknowledge that, while GH does not increase muscle strength, power, or aerobic capacity in healthy adults, it does appear to increase anaerobic capacity. While the ability of GH to increase sprint capacity justifies its ban in sports, it may offer an option of improving physical rehabilitation, as well as physical function and independence in disabled or injured patients.

Safety of GH

GH adverse events have been carefully documented in a review of GH therapy. Most adverse events have
been local-injection-site reactions, which rarely lead to discontinuation. Headache, nausea, and fever have been generally self-limiting and are well tolerated. Adverse events such as edema or carpal tunnel syndrome are seen more often in adults than children, and may be the result of fluid retention caused by GH.\(^6^8\) Adverse events seen particularly in children have included transient idiopathic intracranial hypertension (IIH, also known as pseudotumor cerebri), gynecomastia, and slipped capital femoral epiphysis.\(^7^6,7^7\) The IIH resolved after discontinuation of GH and restarting at a low dose.

There has been particular interest in evaluating the safety of GH treatment of children with ISS, since these children are often described as “normal short children.” Thus, it would be of concern if treating these particular children with GH put them at any significant risk. Therefore, this group of children has been extensively studied from a safety perspective. An evaluation by Quigley et al\(^7^8\) of safety data from the controlled trial of GH therapy of children with ISS\(^7^9\) and the subsequent dose response study,\(^8^0\) as well as an evaluation of >8000 ISS patients followed in a large postmarketing database for children treated with GH,\(^2^7\) have shown that there are no safety issues in GH therapy different from those seen with treatment of GHD.

There have been concerns about cancer associated with GH administration. These issues have been recently reviewed.\(^6^8\) Acromegaly is known to increase the risk of colorectal cancer.\(^5^5\) Epidemiological studies have shown a relationship between tall stature and cancer risk,\(^6^2\) between IGF-I levels and the risk of prostate cancer,\(^5^3\) and an increase in breast cancer associated with levels of free IGF-I.\(^4^4\) One study has suggested that there may be cause for concern because of cases of Hodgkin’s disease and colorectal cancer found in long-term follow-up of patients who had received human-derived GH.\(^5^5\) Although the incidence of these diseases was greater than the population at large, it was not outside the confidence ranges. Further, follow-up of patients receiving human-derived GH in the USA has not shown such a correlation.\(^5^5\) There has been recent concern from analysis of data in French children who were treated with GH between 1985 and 1996, and then followed until 1996 (the Safety and Appropriateness of Growth hormone treatments in Europe [SAGHE] study).\(^8^6\) A retrospective analysis of mortality in this population suggests the possibility of increased cardiovascular disease and bone tumors in adults who received GH as children. The cardiovascular disease was primarily attributed to subarachnoid or intracerebral hemorrhages. Overall cancer mortality rates were not higher than the general population, but bone tumor–related deaths were five times higher than expected. There appeared to be a dose relationship (risk was highest in patients receiving doses >50 mcg/day). However, there was no apparent relationship with duration of GH therapy, which would be expected if the increase in mortality was actually related to GH therapy. Data from other European countries should be available over the next several years, and may serve to shed some light on the SAGhe data. A recent report has examined life expectancy in 99 Ecuadorian people with GH receptor deficiency (GHRD) — that is, who had a defect in their GH receptor leading to IGF-I deficiency.\(^8^7\) The GHRD population had only one cancer (nonfatal), compared with 17% of the control population. Further, there were no cases of diabetes in the GHRD population, compared with 5% in the control population. This study provides strong evidence that the GHRD population has resistance to cancer and diabetes.

Overall, GH has been shown to be a safe hormone when used at recommended doses. There are excellent large databases for evaluation of possible safety signals that occur during treatment with GH, such as the National Cooperative Growth Study (NCGS) and the Kabi International Growth Study (KIGS). What is most needed is long-term adult follow-up of those patients who received GH as children.

**Conclusion**

From careful studies over the past 25 years, GH appears to be a relatively safe hormone, at least during the time that it is being administered. There are few data relating to long-term follow-up, and this is a challenge for the future. GH is a powerful growth-promoting anabolic hormone, which may have further use in treating a number of short stature conditions, for example Russell–Silver syndrome or chondrodystrophies, as well as X-linked vitamin D–resistant rickets. When used to treat CF it may offer stimulation of linear growth, as well as X-linked vitamin D–resistant rickets. When used to treat CF it may offer stimulation of linear growth, as well as better energy balance. GH should not be used in critically ill patients, since it has been associated with increased mortality in this population. It may possibly offer benefit in situations of muscle wasting, including aging, and it does appear to offer some advantage in physical performance, which may lead to uses in treating injured patients who could benefit from increased physical function and independence. Further studies are indicated to determine the risks and benefits, as well as the cost relative to the benefits for a number of conditions.
Disclosure
The authors report no conflicts of interest in this work.

References

